Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.61 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Via The Motley Fool

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Why Novo Nordisk Stock Is Moving Higher Today ↗

November 26, 2025

Patients could soon access higher-dose injections.

Via The Motley Fool

Topics Stocks

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗

November 25, 2025

Via Stocktwits

Novo Nordisk Stock Tumbles: HSBC Downgrades After ‘Lottery Ticket’ Alzheimer’s Bet Fails, But Retail Traders Call Selloff ‘Ridiculous’ ↗

November 24, 2025

Via Stocktwits

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic ↗

November 21, 2025

Via Stocktwits

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗

November 26, 2025

The weight loss drug market may approach almost $100 billion by the end of the decade.

Via The Motley Fool

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Here's Why Novo Nordisk Stock Popped Today ↗

November 25, 2025

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Via The Motley Fool

Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors ↗

November 25, 2025

Discover Novo Nordisk (NVO), a potentially undervalued stock with strong profitability, solid financial health, and a good dividend yield.

Via Chartmill

Why Novo Nordisk Stock Sank 5.6% Today ↗

November 24, 2025

Semaglutide was no better than a placebo.

Via The Motley Fool

Topics Stocks

Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗

November 24, 2025

Via MarketBeat

Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More ↗

November 24, 2025

Stocks were up sharply to start the holiday week.

Via The Motley Fool

Topics Artificial Intelligence Government Stocks

Wondering what's happening in today's pre-market session? ↗

November 24, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗

November 24, 2025

The company said that it is discontinuing the trials.

Via Stocktwits

Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗

November 23, 2025

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Via The Motley Fool

Topics Government

2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗

November 22, 2025

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

Via The Motley Fool

3 Top Dividend Stocks to Buy in November ↗

November 22, 2025

November is a great month to be thankful for opportunities to invest in these fantastic companies.

Via The Motley Fool

Topics Bonds Economy

Big News for Novo Nordisk Stock Investors ↗

November 21, 2025

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.

Via The Motley Fool

What's Going On With Novo Nordisk Stock? ↗

November 21, 2025

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

Via The Motley Fool

Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗

November 20, 2025

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

Via Benzinga

KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds

November 20, 2025

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a...

Via MarketMinute

Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗

November 20, 2025

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Via The Motley Fool

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War ↗

November 19, 2025

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Should Investors Buy Novo Nordisk Stock Near Its Near 52-Week Low? ↗

November 19, 2025

Novo Nordisk is investing aggressively to improve its pipeline of drugs in development.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today